{{ (moduleVm.actions && moduleVm.changeStatus) ? moduleVm.status : '' }} The Antidote Is Finally Here! Idarucizumab, A Specific Reversal Agent for the Anticoagulant Effects of Dabigatran

Purpose of Activity

To provide information about the newly approved novel oral anticoagulant reversal agent, idarucizumab.

Learning Objectives/Outcomes

After completing this continuing education activity you will be able to:

  1. Identify the approval process and indications for the use of idarucizumab.
  2. Recognize the mechanism of action and administration considerations for idarucizumab.
Price: $21.95

Credits:

  • ANCC 2.0 CH / 2.0 APH
  • DC - BON 2.0 CH
  • FL - BON 2.0 CH
  • GA - BON 2.0 CH

Lippincott Williams & Wilkins is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center's Commission on Accreditation. This activity is also provider approved by the California Board of Registered Nursing, Provider Number CEP 11749. Lippincott Williams & Wilkins is also an approved provider of continuing nursing education by the District of Columbia Board of Nursing, #50-1223, Florida Board of Nursing, #50-1223, and Georgia Board of Nursing, #50-1223. Your certificate is valid in all states.

Awarded Advanced Pharmacology Hours







Test Code: CNS0316
Published: Mar/Apr 2016
Expires: 3/6/2020
Passing Score: 13/18 (72%)
Authors: Patricia Anne O'Malley, PhD, RN, CNS